Acute Kidney Injury Associated with Linagliptin

doi:10.1155/2016/5695641

Paper

Acute Kidney Injury Associated with Linagliptin

Published Feb 14, 2016 · Deepak K Nandikanti, A. Gosmanov, E. Gosmanova

Case Reports in Endocrinology

7

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

Linagliptin is a dipeptidyl peptidase-IV (DPP-IV) inhibitor that is approved for the treatment of type 2 diabetes mellitus. About 5% of linagliptin is eliminated by the kidneys and no dose adjustment is recommended in kidney impairment. We report a first case of linagliptin-associated acute kidney injury (AKI) in a patient with preexisting chronic kidney disease (CKD). We hypothesize that AKI was due to renal hypoperfusion from linagliptin-induced natriuresis and intravascular volume contraction in the setting of concomitant lisinopril use, which is known to impair autoregulation and potentiate hypotension-induced AKI. It may be prudent to exert caution and closely monitor kidney function when initiating linagliptin in combination with ACE-inhibitors in CKD patients.

Case Report

Study Snapshot

Linagliptin may cause acute kidney injury in patients with chronic kidney disease, requiring caution and monitoring when combined with ACE-inhibitors.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Acute Kidney Injury Associated with Linagliptin

References

Citations